3+3 dose-escalation design
The 3+3 design uses fixed rules for small cohorts to guide escalation; it does not fit a dose-toxicity model.
Why this level?
not one of the five research areas this hierarchy covers. NHMRC 2009 sourceDose selection is a feasibility and safety question, not one of the five research areas this hierarchy covers. It does not establish comparative treatment benefit.
Fit
When to use it, and when not to
Use it when
- You need to select a dose for later study under a prespecified safety plan.
- The toxicity outcome and its observation window can guide the next allocation.
Not when
- You need to choose the allocation approach first. Compare dose-finding designs. Read: Choosing a dose-finding design
- You need to establish treatment benefit against a comparator. Use a randomized trial. Read: Randomized controlled trial
Before you start
What you need
- Toxicity definition and targetDefine a dose-limiting toxicity and the full assessment window before recruitment.
- Dose levels and safety limitsFix the starting dose, allowed moves, stopping rules and independent safety oversight.
- Simulated trial scenariosVary toxicity curves, accrual and delayed harm. Check selection accuracy and exposure to unsafe doses.
- Pending toxicity is not absence of toxicity.How to check: Wait for the required window or use a validated extension designed for partial follow-up.
- The dose ordering and safety target fit the treatment.How to check: Toxicity-focused dose selection may not identify the best benefit-risk balance or biological dose.
Plain language
How it works
Treat three patients at a dose and complete the toxicity window. A common rule escalates if none has a dose-limiting toxicity. One toxicity expands the cohort to six. At least two toxicities stop escalation at that dose. After expansion, one of six can permit escalation; at least two of six stop it. The protocol must specify the final dose choice and safety stopping rules.
The rule is simple but its dose-selection behavior depends on the toxicity curve and starting dose. It does not directly choose an arbitrary target toxicity probability. Simulate the complete protocol and assess both unsafe and ineffective dosing.
Worked example
A worked example
- Setting
- An early-phase trial follows a prespecified toxicity window.
- Question
- What do the observed counts imply under the stated design?
- Approach
- Three patients complete the window at one dose; one has a dose-limiting toxicity. The stated 3+3 rule expands that dose.
- Result
- One of three patients has a toxicity, about 33 in 100. The cohort expands from 3 to 6 patients.
- What it means
- The next decision depends on all six outcomes. This observed share is not a precise toxicity risk.
In practice
Recent studies PubMed search · not vetted
Watch out
Common mistakes
The one to remember
A familiar cohort rule is not a guarantee of safety or correct dose selection. State the exact variant, final selection rule and stopping policy.
- Equating dose selection with proof of efficacy.Instead: Selection is uncertain. Confirm benefit in a suitable later trial.
- Changing allocation rules after a worrying result.Instead: Apply the prespecified safety and stopping rules with the safety team.
Inside Mallard
How Mallard uses this
Plans do not link to this design yet. Mallard has no sample-size form for the 3+3 dose-escalation design. A plan sized by simulation gets no headline sample size; Mallard does not run that simulation.
design.three_plus_three, the id a plan cue records.How to report it
Use CONSORT-DEFINE to report the dose-selection goal, toxicity window, allocation, safety and stopping rules, deviations and participant flow. Separate observed toxicity from model estimates. State the final dose recommendation and its uncertainty. A reporting guideline is not a design manual: use it to make the study transparent, not as a substitute for careful design. Check the target journal's own requirements as well, which this page cannot know.
Related Learn pages
Related designs and methods
Evidence
Sources & further reading
- Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents (opens in a new tab) · PLoS One · doi 10.1371/journal.pone.0051039
- Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials (opens in a new tab) · Clin Cancer Res · doi 10.1158/1078-0432.CCR-16-0592
- Dose escalation methods in phase I cancer clinical trials (opens in a new tab) · J Natl Cancer Inst · doi 10.1093/jnci/djp079
- Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance (opens in a new tab) · BMJ · doi 10.1136/bmj-2023-076387